

ElisaRSR[™] TRAb 2nd Generation

TSH Receptor Autoantibody 2nd Generation ELISA Kit - Instructions for use



RSR Limited

Parc Ty Glas, Llanishen, Cardiff CF14 5DU United Kingdom

Tel.: +44 29 2068 9299 Fax: +44 29 2075 7770 Email: info@rsrltd.com Website: www.rsrltd.com



Advena Ltd. Tower Business Centre, 2nd Flr., Tower Street, Swatar, BKR 4013 Malta.

INTENDED USE

The RSR TSH receptor (TSHR) autoantibody (TRAb) ELISA kit is intended for use by professional persons only for the quantitative determination of TRAb in human serum. Hyperthyroidism in Graves' disease is due to the presence of autoantibodies to the TSHR and measurement of these autoantibodies can be useful in disease diagnosis and management.

REFERENCES

J. Bolton et al

Measurement of thyroid stimulating hormone receptor autoantibodies by ELISA Clin. Chem. 1999 45: 2285-2287

K. Kamijo

TSH receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH receptor and coated tube radioassay using human recombinant TSH receptor

Endocrine Journal 2003 50:113-116

B. Rees Smith et al

A new assay for thyrotropin receptor autoantibodies

Thyroid 2004 14: 830-835

ASSAY PRINCIPLE

In RSR's TRAb ELISA, TRAb in patients' sera, calibrators and controls are allowed to interact with TSHR coated onto ELISA plate wells. After a 2 hour incubation, the samples are discarded leaving TRAb bound to the immobilised TSHR. TSH-Biotin is added in a 2nd incubation step, where it interacts with immobilised TSHR which have not been blocked by the bound TRAb from patient sera, calibrators or controls. The amount of TSH-Biotin bound to the plate is then determined in a 3rd incubation step by addition of Streptavidin Peroxidase (SA-POD), which binds specifically to Biotin. Excess unbound SA-POD is then discarded and the addition of the peroxidase substrate 3,3',5,5'-tetramethylbenzidine (TMB) results in the formation of a blue colour. This reaction is stopped by the addition of stop solution causing the well contents to turn from blue to yellow. The absorbance of the yellow reaction mixture at 450nm is then read using an ELISA plate

reader. A lower absorbance indicates the presence

of TRAb in a test sample as TRAb inhibits the binding of TSH-Biotin to TSHR coated plate wells. The measuring range is 1 - 40 u/L (NIBSC 08/204).

STORAGE AND PREPARATION OF TEST SERUM SAMPLES

Sera to be analysed should be assayed soon after separation or stored, preferably in aliquots, at or below $-20^{\circ}C.~150~\mu L$ is sufficient for one assay (duplicate $75~\mu L$ determinations). Repeated freeze thawing or increases in storage temperature must be avoided. Incorrect storage of serum samples can lead to loss of TRAb activity. Do not use lipaemic or haemolysed serum samples. Do not use plasma in the assay. When required, bring test sera to room temperature (20 - 25°C) and mix gently to ensure homogeneity. Centrifuge the serum prior to assay (preferably for 5 minutes at 10-15,000 rpm in a microfuge) to remove any particulate matter. Please do not omit this centrifugation step for sera that are cloudy or contain particulates.

IFU SYMBOLS

Symbol	Meaning
CE	EC Declaration of Conformity
IVD	In Vitro Diagnostic Device
REF	Catalogue Number
LOT	Lot Number
[]i	Consult Instructions
***	Manufactured by
Σ	Sufficient for
\subseteq	Expiry Date
2°C/8°C	Store
CONTROL _	Negative Control
CONTROL +	Positive Control

MATERIALS REQUIRED AND NOT SUPPLIED

Pipettes capable of dispensing 50 μ L, 75 μ L and 100 μ L.

Means of measuring out various volumes to reconstitute or dilute reagents.

Pure water.

ELISA Plate reader suitable for 96 well formats and capable of measuring at 450nm.

ELISA Plate shaker, capable of 500 shakes/min (not an orbital shaker).

ELISA Plate cover.

PREPARATION OF REAGENTS SUPPLIED

Store unopened kits and all kit components (A-K) at 2–8°C

TSH Receptor Coated V 12 breakapart strips of 8 in a frame and sealed in a	
stand at room temperature	foil bag. Allow to e (20-25°C) for at
A Ensure wells are fitted provided. After opening, record wells to the original foil because the foil bag in the bag with desiccant provided.	firmly into frame return any unused bag and seal, then e self-seal plastic ded. Store at 2-
8°C for up to expiry of kit	
Start Buffer B 10 mL Ready for use	
C1- 4	
Negative Control 1.0 mL Ready for use	
D2 1.0 mL Ready for use	el for range)
E TSH-Biotin 3 vials Lyophilised Reconstitute each vial reconstitution buffer for When more than one via pool the vials and mix g Store at 2–8°C for up to each state.	al is to be used, ently before use.
Reconstitution Buffer for F 15 mL Ready for use	or TSH-Biotin
Streptavidin Peroxidase	(SA-POD)
0.75 mL	
G	
Dilute 1 in 20 with diluen For example, 0.5 mL (G Store at 2–8°C for up to e) + 9.5 mL (H).
Diluent for SA-POD H 15 mL Ready for use	
Peroxidase Substrate (T I 15 mL Ready for use	MB)
Concentrated Wash Sol 100 mL Concentrated Dilute to 1 litre with pure Store at 2-8°C for up to e	water before use.
K 10 mL Ready for use	

ASSAY PROCEDURE

Allow all reagents and test samples to stand at room temperature (20-25°C) for at least 30 minutes before use. A repeating Eppendorf type pipette is recommended for steps 1, 5, 8, 10 and 11. Duplicate determinations are strongly recommended for test sera, calibrators and controls.

- 1. Pipette 75 μ L of start buffer (B) into each well to be used, leaving the last well empty for a blank (see step 12).
- 2. Pipette 75 μL of test sera, calibrators (C1-4) and controls (D1 and D2) into respective wells (start with the 40 u/L calibrator and descend down the plate to the negative control and then test sera), leaving the last well blank.
- 3. Cover the frame and shake the wells for 2 hours at room temperature on an ELISA plate shaker (500 shakes per min.).
- 4. After incubation, aspirate samples by use of a plate washing machine, or discard the samples by briskly inverting the frame of wells over a suitable receptacle. Wash the wells once with diluted wash solution (J), and aspirate the wash by use of a plate washing machine or discard the wash by briskly inverting the frame of wells over a suitable receptacle. Tap the inverted wells gently on a clean, dry, absorbent surface to remove excess wash solution (only necessary if washing plate by hand).
- Fipette 100 μL of reconstituted TSH-Biotin (E) into each well (except blank). Avoid splashing the material out of the wells during addition.
- **6.** Cover the frame, and incubate at room temperature for 25 minutes without shaking.
- **7.** Repeat wash step 4.
- 8. Pipette 100 μL of diluted SA-POD (G) into each well (except blank), cover the frame and incubate at room temperature for 20 minutes without shaking.
- 9. After incubation, aspirate samples by use of a plate washing machine, or discard the samples by briskly inverting the frame of wells over a suitable receptacle. Wash the wells twice with diluted wash solution (J) followed by once with pure water (to remove any foam) and tap the inverted wells gently on a clean, dry, absorbent surface to remove excess wash solution (if a plate washing machine is used, the plate can be washed 3 times with diluted wash solution (J) only).
- 10. Pipette 100 μ L of TMB (I) into each well (including blank) and incubate in the dark at room temperature for 30 minutes without shaking.
- 11. Pipette 50 μL stop solution (K) to each well (including blank) cover the frame and shake for approximately 5 seconds on an ELISA plate shaker. Ensure substrate incubations are the same for each well.

12. Within 15 minutes, read the absorbance of each well at 450 nm using an ELISA plate reader, blanked against the well containing 100 μ L of TMB (I) and 50 μ L stop solution (K) only.

RESULT ANALYSIS


A calibration curve can be established by plotting calibrator concentration on the x-axis (log scale) against the absorbance of the calibrators on the y-axis (linear scale). The TRAb concentrations in patients' sera can then be read off the calibration curve [plotted at RSR as a spline log/lin curve (smoothing factor = 0)]. The negative control can be assigned a value of 0.1 to assist in computer processing of assay results. Other data reduction systems can be used. Results can also be expressed as inhibition (%I) of TSH binding calculated using the formula:

$$100 \, x \left(1 - \frac{\text{test sample absorbance at } 450 \, \text{nm}}{\text{negative control (D1) absorbance } 450 \, \text{nm}}\right)$$

Samples with high TRAb concentrations can be diluted in kit negative control (D1). For example, 20 μ L of sample plus 180 μ L of negative control to give a 10x dilution. Other dilutions (e.g. 100x) can be prepared from a 10x dilution or otherwise as appropriate. Some sera will not dilute in a linear way and we suggest that the dilution giving a value closest to 50% inhibition is used for calculation of TRAb concentration.

TYPICAL RESULTS (example only, not for use in calculation of actual results)

Sample	A450 (minus blank)	%I	u/L
Control D1	2.00	0	0
C1	1.70	15	1
C2	1.50	25	2
С3	0.65	68	8
C4	0.15	93	40
Control D2	1.26	37	3.5



ASSAY CUT OFF

	u/L
Negative	≤1 u/L
Equivocal	1.1 – 1.5 u/L
Positive	>1.5 u/L

This cut off has been validated at RSR. However each laboratory should establish its own normal and pathological reference ranges for TRAb levels. Also it is recommended that each laboratory include its own panel of control samples in the assay.

CLINICAL EVALUATION

Clinical Specificity

154 Sera from healthy blood donors were assayed in the RSR TRAb ELISA kit. 152 (99%) were identified as being negative for TRAb.

Clinical Sensitivity

50 Sera from patients diagnosed with Graves' disease were assayed using the RSR TRAb ELISA kit. 49 (98%) were identified as being positive for TRAb. 1 sample (2%) was identified as being within the equivocal range.

Functional Sensitivity

A plot of inter assay CV against u/L indicates a 20% CV occurring at 0.60 u/L.

Lower Detection Limit

The kit negative control was assayed 32 times and the mean and standard deviation calculated. The lower detection limit at 2 standard deviations was 0.21~u/L.

Inter Assay Precision

Sample	u/L (n = 20)	CV (%)
1	3.9	12.9
2	5.4	10.9

Intra Assav Precision

Sample	u/L (n = 25)	CV (%)
1	1.8	7.1
2	7.8	2.2

Clinical Accuracy

Analysis of sera from patients with autoimmune diseases other than Graves' disease indicated no interference from autoantibodies to thyroglobulin; thyroid peroxidase; glutamic acid decarboxylase; 21-hydroxylase; acetylcholine receptor; dsDNA or from rheumatoid factor.

Interference

No interference was observed when samples were spiked with the following materials; haemoglobin at 5 mg/mL; bilirubin at 0.2 mg/mL; Intralipid up to 30 mg/mL, human LH up to 10 u/mL; hCG up to 160 u/mL; human FSH up to 70 u/mL and human TSH up to 3 u/L.

SAFETY CONSIDERATIONS

Streptavidin Peroxidase (SA-POD)

Signal word: Warning Hazard statement(s)

H317: May cause an allergic skin reaction

Precautionary statement(s)

P280: Wear protective gloves/protective clothing/

eye protection/face protection

P302 + P352: IF ON SKIN: Wash with plenty of

soap and water

P333 + P313: If skin irritation or rash occurs: Get

medical advice/attention

P362 + P364: Take off contaminated clothing and

wash it before reuse

This kit is intended for *in vitro* use by professional persons only. Follow the instructions carefully. Observe expiry dates stated on the labels and the specified shelf life for coated wells, diluted or

reconstituted reagents. Refer to Safety Data Sheet for more detailed safety information. Material of human origin used in the preparation of the kit has been tested and found non reactive for HIV1 and 2 and HCV antibodies and HBsAg but should, nonethe-less, be handled as potentially infectious. Wash hands thoroughly if contamination has occurred and before leaving the laboratory. Sterilise all potentially contaminated waste, including test specimens before disposal. Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materials should be handled as potentially infectious. Some components contain small quantities of sodium azide as preservative. With all kit components, avoid ingestion, inhalation, injection and contact with skin, eyes and clothing. Avoid formation of heavy metal azides in the drainage system by flushing any kit component away with copious amounts of water.

ASSAY PLAN

ASSAY PLAN	
Allow all reagents and samples to reach room temperature (20-25°C) before use.	
Pipette:	75 μL Start buffer into each well (except blank)
Pipette:	75 μL Calibrators (starting with the highest concentration and descending to
	lowest), controls, patient sera (except blank)
Incubate	2 Hours at room temperature on an ELISA plate shaker at 500 shakes/min
Aspirate/Decant:	Plate
Wash:	Plate once on automatic washer (or wash once, invert and tap dry on absorbent
	material for manual washing)
Pipette:	100 μL TSH-Biotin (reconstituted) into each well (except blank)
Incubate:	25 Minutes at room temperature without shaking
Aspirate/Decant:	Plate
Wash:	Plate once as above
Pipette:	100 μL SA-POD (diluted 1:20) into each well (except blank)
Incubate:	20 Minutes at room temperature without shaking
Aspirate/Decant:	Plate
Wash:	Plate three times on automatic washer (or wash twice, rinse once with pure water
	and dry on absorbent material for manual washing)
Pipette:	100 μL TMB into each well (including blank)
Incubate:	30 Minutes at room temperature in the dark without shaking
Pipette:	50 μL Stop solution into each well (including blank) and shake for 5 seconds
Read absorbance at 450 nm, within 15 minutes of adding stop solution	
Do not perform the assay at temperatures above 25°C.	